Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Context Therapeutics Inc (NQ: CNTX ) 1.890 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 51 Open 1.890 Bid (Size) 1.820 (1) Ask (Size) 1.950 (2) Prev. Close 1.890 Today's Range 1.890 - 1.890 52wk Range 0.7700 - 2.750 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody September 23, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors September 04, 2024 The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy From Context Therapeutics Inc. Via GlobeNewswire Performance YTD +52.42% +52.42% 1 Month -22.86% -22.86% 3 Month +5.59% +5.59% 6 Month +52.42% +52.42% 1 Year +35.97% +35.97% More News Read More Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results August 07, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations August 01, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 July 10, 2024 From Context Therapeutics Inc. Via GlobeNewswire Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight May 30, 2024 Via InvestorPlace The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains May 22, 2024 Via InvestorPlace CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024 May 08, 2024 Via InvestorPlace Context Therapeutics Reports First Quarter 2024 Operating and Financial Results May 08, 2024 From Context Therapeutics Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 02, 2024 Via Benzinga Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Announces $100 Million Private Placement May 02, 2024 From Context Therapeutics Inc. Via GlobeNewswire Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers April 01, 2024 From Context Therapeutics Inc. Via GlobeNewswire CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 March 21, 2024 Via InvestorPlace Context Therapeutics Reports Full Year 2023 Operating and Financial Results March 21, 2024 From Context Therapeutics Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session January 12, 2024 Via Benzinga Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session December 15, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session December 15, 2023 Via Benzinga Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday December 15, 2023 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Friday's Pre-Market Session December 08, 2023 Via Benzinga Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results November 09, 2023 From Context Therapeutics Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 31, 2023 Via Benzinga Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 October 31, 2023 From Context Therapeutics Inc. Via GlobeNewswire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
